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and after CDI events. The CDPH HAI Program is using these analyses to inform CDI 
prevention outreach to California healthcare facilities and provider networks.
Disclosures. All authors: No reported disclosures.
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Background. An abrupt change in baseline CDI from 2016 to 2017 prompted a 
response team task force including senior administration, the CMO, infection preven-
tion, environmental services, laboratory, pharmacy, emergency department (ED), and 
nursing to address the problem.
Methods. Hospital-acquired (HA) and community-acquired (CA) CDI cases 
were tracked using an epidemic curve and institutional case mapping. A multipronged 
intervention was implemented that included molecular typing of isolates, quarterly ter-
minal cleaning of the ED, improved CDI screening and testing, intensified antimicro-
bial stewardship (AS) with mandatory education for key clinicians, and rigorously 
enhanced enforcement of hand hygiene with secret observers and directed feedback. 
Pre-, mid-, and fully-implemented intervention HA and CA CDI rates were observed.
Results. Ninety-five percent of CA CDI and 98% of all patients who developed 
HA CDI were admitted through the ED. Cases of CDI were distributed throughout 
the hospital. The genotyping did not identify a single strain outbreak. Sixteen percent 
of all CDI samples (23% of CA and 9% of HA cases) sent to the DOH tested positive 
for BINAP1. Preintervention rates of HA CDI were found to be lower than mid-inter-
vention rates (2.4, 95% CI= 1.5–3.1 vs. 4.3, 95% CI= 1.13–7.37). HA CDI rates after 
full-intervention in fourth quarter 2017 and first quarter 2018 trended toward baseline 
(2.1, 95% CI = 0–5.93) but had not achieved statistical improvement (Figure 1). A sig-
nificant correlation between HA CDI rates and CA CDI rates was not found (r = 0.241, 
P < 0.5), suggesting that HA CDI rates were not driven by CA CDI rates. Hospital and 
ED hand hygiene improved significantly; hospital preintervention = 0.84 vs. interven-
tion = 0.91, P < 0.01; ED hand hygiene preintervention = 0.72 vs. intervention = 0.86, 
P < 0.04. No statistically significant changes in antimicrobial use were noted.
Conclusion. A  rapid, aggressive team-based approach for a CDI outbreak suc-
cessfully reversed a rising rate and SIR. Although no one specific intervention was 
clearly responsible for the reversal, we did observe a statistically significant increase 
in hand hygiene. This outbreak and its management illustrate the importance of active 
surveillance and a rapid team-based response to CDI outbreaks.
Disclosures.All authors: No reported disclosures.
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Background. Diagnosis of Clostridium difficile infection (CDI) is challenging. 
The reason is two-fold: (a) lack of unique symptoms and (b) lack of a gold standard test 
for CDI. We studied variation in CDI rates when different diagnostic algorithms were 
utilized. In addition, we compared patients who met the clinical definition of CDI with 
different diagnostic assays.
Methods. This is a retrospective study at an academic medical center (401-bed) 
conducted over 12 months (January 2017–December 2017). A stool sample that tested 
positive by polymerase chain reaction (PCR) for C. difficile (n = 81) was then tested for 
glutamate dehydrogenase (GDH) and toxin enzyme immunoassay (EIA). Additionally, 
all PCR-positive cases were also tested for toxin production by cytotoxic neutralization 
assay (CCNA). Clinical C. difficile was defined as three or more loose stools within 
24-hour time period. Clinical data were obtained from review of charts. This definition 
was applied to all community-onset and hospital-onset cases.
Results. C.  difficile was detected in 81 symptomatic patients by PCR test. Of 
these, 41.9% met the clinical definition of diarrhea. Of the 81 patients, toxin EIA and 
GDH were positive in 29.6% (24/81) and 4% met the clinical definition. CCNA was 
positive in 66.67% (54/81) and only 9% met the clinical definition. The CDI rate (per 
10,000 patient days) was 10.2 in the PCR positive group; 3.02 in toxin EIA and GDH 
group and 6.81 in CCNA group. Duration of diarrhea was longer when functional 
assays (toxin EIA and/or CCNA) were positive, i.e., 48 hours after diagnosis, 22.7% 
(18/79) of patients with a positive CCNA and EIA had diarrhea while only 6% (3/49) 
of the patients with GDH and PCR positive tests (nonfunctional assays) had diarrhea 
(P = 0.013). The difference was statistically significant. All 81 patients were started on 
CDI treatment within 24 hours of diagnosis. Of note, there was no laxative use contrib-
uting to symptoms in these cases.
Conclusion. CDI rates differ with various diagnostic algorithms. Duration of 
diarrhea was significantly longer when functional assays (CCNA or toxin EIA) were 
positive. Inclusion of both a functional assay (EIA and/or CCNA) and a clinical def-
inition of CDI can improve the diagnostic accuracy of CDI. A combination of clinical 
judgment and functional assays is required for an accurate diagnosis of CDI.
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Background. Community-acquired Clostridium difficile infections (CA-CDI) are 
under a mandatory reporting program starting in August 2004 across 95 healthcare 
institutions from the QCISP. There has been a slow and continuous increase in the 
incidence rate of hospitalized CA-CDI since 2007 without any known obvious explan-
ation. The objectives of this study were to characterize cases of CA-CDI and investigate 
the potential causes of this increase.
Methods. A  retrospective study was carried out using a survey sent to eligible 
healthcare institutions. Hospitals participating in QCISP that reported ≥3 cases of 
CA-CDI in 2016–2017 were invited to participate. To identify potential causes of the 
apparent increase in CA-CDI incidence, they were asked to provide clinical infor-
mation regarding up to three cases of CA-CDI for two distinct surveillance years 
(2011–2012 and 2016–2017). To characterize each CA-CDI cases, a broad range of 
demographic, clinical, and laboratory variables were collected, including medical his-
tory, history of contact with primary and secondary healthcare institutions, previous 
antibiotics use as well as laboratory diagnostic test. A χ2 test have been used to test year 
differences in indicator distributions.
Results. A  total of 49 healthcare institutions provided data on 172 cases of 
CA-CDI. Overall, 92% (n = 159) of them meet the QCISP CA-CDI criteria definition. 
Among them, most patients (67%) were female, and average age was 66.7 ± 20.5 year 
old. Seventy-four percent had received antibiotic in the previous year. Between the two 
years, there was no significant change in the socio-demographic and clinical variables 
of CA-CDI cases. The proportion of patients receiving immunosuppressive drugs and 
proton pump inhibitors at the time of diagnosis was 11% and 45%, respectively. The 
proportion of cases visiting ambulatory healthcare settings during the year previous to 
patient admission increased from 61% (2011–2012) to 69% (2016–2017) (P = 0.18). 
Moreover, there was a significant increase in the proportion of CA-CDI diagnosed by 
laboratory PCR test (from 8% to 55%; P < 0.0001).
Conclusion. This study provided important data to characterize CA-CDI using 
the QCISP. The increase in the use of PCR is associated with the incidence of CA-CDI 
but may not be the cause of it.
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Background. Antibiotic use is a well-known risk factor for development of CDI, 
and there is preliminary evidence suggesting concomitant antibiotic use may result in 
poor outcomes, including death. This work investigated the effect of concomitant anti-
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Methods. We conducted a national retrospective study of Veterans with a first 
CDI between 2010 and 2014, defined as a positive C. difficile toxin(s) and no episode 
in the year prior. Those treated with guideline recommended CDI treatment were 
included (10–14  days of PO or IV metronidazole, PO or PR vancomycin, or fidax-
omicin). The exposure of interest was any non-CDI antibiotic use during CDI treat-
ment; and the outcome was all cause death within 30 days of the end of CDI treatment. 
Inverse probability of treatment weighted Cox proportional hazards models were used 
to estimate the effect of concomitant antibiotic use on time to mortality. Weights were 
derived from propensity score modeling of the probability of exposure to antibiotics 
during CDI treatment as a function of potential confounders. Sensitivity analyses by 
antibiotic class were conducted.
Results. Of the 9,517 patients included in the study cohort, mean age was 
65.3 years (±SD 14.6), 92.5% (n = 8,802) were male, and 75.03% (n = 7,141) were white. 
Half were exposed to non-CDI antibiotics during CDI treatment (51.8%, n = 4,925) 
and 8.9% (n = 849) died. In unadjusted and adjusted analyses, concomitant antibiotic 
use was associated with death (HR 5.74, 95% CI 4.75–6.93; aHR 2.39, 95% CI 2.07–
2.75). Advanced generation cephalosporin (aHR 2.36, 95% CI 2.05–2.71), β-lactam/β-
lactamase inhibitor combinations (aHR 1.45, 95% CI 1.16–1.82), and clindamycin 
(aHR 1.95, 95% CI 1.26–3.02) were associated with death, while fluoroquinolone use 
was not (aHR 0.97, 95% CI 0.84–1.12)
Conclusion. Among our national cohort, concomitant antibiotic use was common 
during CDI treatment. Any concomitant antibiotic use increased the risk of death; how-
ever, results suggest risk might vary by antibiotic class. Results support continued efforts 
in the reduction of unnecessary antibiotic use during CDI treatment, and future studies 
into which antibiotics may have the least risk of death when treatment is necessary.
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Background. The estimated prevalence of Clostridioides difficile infection (CDI) 
in several South Asian countries is 10.5%, similar to that in North America and 
Europe. However, the epidemiology of CDI in Bangladesh is unknown. We aimed to 
assess the prevalence of CDI and assess hospital environmental contamination of tox-
igenic C. difficile in Bangladesh.
Methods. This was a prospective observational cohort study at two large tertiary 
care centers in Dhaka, Bangladesh, conducted from January 2017 to December 2017. 
Stool samples were collected from hospitalized adults with diarrhea (≥3 loose stools in 
a 24-hour period) and antimicrobial exposure within the past 30 days. Hospital envir-
onmental samples were collected by swabbing surfaces of common areas in the hospi-
tal. All samples underwent toxigenic culture. C. difficile isolates were tested for toxins 
A and B and PCR-ribotyped.
Results. Of 204 stool samples collected, 16 (7.8%) were positive for toxigenic C. dif-
ficile. Patients with CDI shared a room with significantly more patients (Table 1). Of 392 
environmental samples, 48 (12.2%) were positive for toxigenic C. difficile, which was more 
common in patient care vs. nonpatient care areas (14.4% vs. 7.8%, P = 0.057). Twelve 
clinical stool isolates and 42 environmental isolates were ribotyped. Ribotypes identified 
in stool isolates were F017 (50%), FP053-163 (17%), FP435 (17%), F106 (8%), and F014-
020 (8%). With the exception of FP435, these were also the most common ribotypes in 
environmental isolates: F017 (24%), FP053-163 (12%), F106 (26%), and F014-020 (10%).
Conclusion. For the first time, we report the prevalence of CDI and ribotypes in 
at risk patients in Bangladesh. Rates and ribotypes are similar to other resource-rich or 
resource-limited countries.







(n = 16) P
Female sex, n (%) 77 (41) 9 (56) 0.234
Age, years, median (IQR) 46 (32–58) 39 (25–53) 0.212
Hospital A, n (%) 149 (79) 13 (81) >0.99
Length of prior hospital stay, 
days, median (IQR)
13 (7–23) 14 (8–32) 0.798
Duration of previous antibiotics, 
days, median (IQR)
10 (7–17) 12 (6–20) 0.687
Number of patients in the same 
room, median (IQR)
13 (7–19) 19 (14–20) 0.009
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Background. The patients undergoing orthopedic surgery may have many risk 
factors of Clostridium difficile infection (CDI), including increased age, multiple 
underlying comorbidities, the use of perioperative antibiotics, and prolonged length 
of stay. The aim of this study was to identify prevalence, risk factor, and outcome of 
postoperative CDI in patients who underwent orthopedic surgery.
Methods. We performed a retrospective cohort study including all patients aged 
≥18 years who underwent orthopedic surgery from January 2016 through December 
2017 in a tertiary care hospital in Seoul, South Korea.
Results. During the study period, 7,369 episodes of orthopedic surgery were iden-
tified. The prevalence of C. difficile infection was 7.7 cases per 1,000 surgical procedures 
(95% confidence interval, 6.0–10.0). The risk of CDI was the highest among patients 
who underwent spine surgery (33.8 cases per 1,000 surgical procedures), followed by 
hip/femur surgery (12.4), knee (3.8), and extremity (3.2). The risk of CDI increased 
according to the increase in duration of proton pump inhibitor: 0.1% (no use), 0.3% 
(1–7  days), and 2.7% (>7  days, P < 0.001). The independent risk factors associated 
with postoperative CDI were age (odds ratio [OR] per 1-year increase, 1.04; P < 0.001), 
Charlson comorbidity index score (OR per 1-point increase, 1.26; P < 0.001), duration 
of proton pump inhibitor (OR per 1-day increase, 1.02; P < 0.001), and operation time 
(OR per 1-hour increase, 1.30; P = 0.003). Of 6,724 episodes of surgical procedure for 
which patients received exclusively perioperative antibacterial prophylaxis, 22 episodes 
of postoperative CDI occurred (3.2 cases per 1,000 surgical procedures). Among this 
subgroup, the risk of CDI increased according to increase in duration of antibacter-
ial prophylaxis: 0% (<24 hour), 0.28% (1–7 days), and 1.27 (>7 days; P < 0.001). After 
adjusting confounding factors, duration of perioperative antibacterial prophylaxis 
remained a significant risk factor for postoperative CDI (OR per 1-day increase, 1.11; 
P < 0.001). Patients with CDI had a higher rate of postoperative mortality (10.5% vs. 
0.6%; P < 0.001) and an increased length of hospital stay (mean 42 vs. 10 days; P < 0.001).
Conclusion. Judicious use of proton pump inhibitor and avoiding of extension of 
prophylactic antibiotics can reduce postoperative CDI after orthopedic surgery.
Disclosures.All authors: No reported disclosures.
473. Molecular Typing of Clostridium difficile: Concordance Between PCR-
Ribotyping and Multilocus Sequence Typing (MLST)
Xiong Wang, DVM, PhD1; Stacy Holzbauer, DVM, MPH1; Kelly Pung, 
BS1; Maria Bye, MPH1; Michelle Adamczyk, BS2; Ashley Lyn Paulick, BS2; 
Nicholas Vlachos, MS2; Alice Guh, MD, MPH2; Alison S. Laufer-Halpin,  PhD2; Maria 
S. Karlsson, PhD2; Dave Boxrud, MSc1 and the Emerging Infections Program CDI 
Workgroup; 1Minnesota Department of Health, Saint Paul, Minnesota, 2Division of 
Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, 
Georgia
Session: 59. Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018: 12:30 PM
Background. Clostridium difficile infection (CDI) incidence has increased dra-
matically in the past decade, making CDI one of the most common causes of infectious 
diarrhea and an urgent public health threat. Understanding the biological features and 
spread of C. difficile strains can help target control efforts. PCR-ribotyping, the current 
method of choice for C. difficile typing, remains subjective and challenging for inter-
laboratory comparisons. Multilocus sequence typing (MLST), based on the alleles of 
seven housekeeping genes, represents a more robust tool that would enhance interlab-
oratory reproducibility. However, a comprehensive translation system to ribotyping is 
a prerequisite. Here, we describe the concordance between MLST and PCR-ribotyping.
Methods. The Centers for Disease Control and Prevention’s (CDC) Emerging 
Infections Program (EIP) conducts CDI surveillance in 10 US sites. C. difficile isolates 
cultured from a subset of cases underwent capillary-based PCR-ribotyping at CDC. 
A representative sample, selected from the top 30 ribotypes (RTs), underwent whole 
genome sequencing (WGS) at Minnesota Department of Health. An additional subset 
of isolates, representing the top 10 RTs, underwent WGS at CDC. At both laboratories, 
the Illumina MiSeq platform was used to obtain 250 bp paired-end sequencing reads. 
MLST analyses were done using the pubMLST C. difficile scheme.
Results. A total of 479 C. difficile isolates, including at least 10 isolates for each RT, 
were analyzed by WGS. Among the 30 RTs represented, 35 different MLST sequence 
types (STs) were identified. Twenty-two of the RTs (including 027)  were each asso-
ciated with a single unique ST, while 8 RTs (020, 014, 015, 076, 046, 153–251, A27, 
and 075) presented more genetic diversity with single-locus or double-locus variants, 
resulting in multiple STs within one ribotype. There were two instances of two different 
RTs sharing the same ST.
Conclusion. Multilocus sequence typing and PCR-Ribotyping showed compar-
able discriminatory abilities. However, the ST is not always predictive of the RT and 
vice versa. This represents the first step toward a transition to using WGS for standard 
C. difficile typing.
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